This study indicates that GSDMB may be recognized as a potential biomarker associated with poor prognosis, which can be used to detect ccRCC patients that have clinical outcomes which are poor and could have a distinct function in immune infiltration. The gene discussed is GSDMB; the disease is nonpapillary renal cell carcinoma.